{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:27:13Z","timestamp":1789273633863,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2016,8,19]],"date-time":"2016-08-19T00:00:00Z","timestamp":1471564800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s10067-016-3379-6","type":"journal-article","created":{"date-parts":[[2016,8,19]],"date-time":"2016-08-19T06:04:20Z","timestamp":1471586660000},"page":"2615-2618","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis"],"prefix":"10.1007","volume":"35","author":[{"given":"C.","family":"Giraud","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Tatar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Soubrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,19]]},"reference":[{"key":"3379_CR1","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.30158","volume":"63","author":"JM Kremer","year":"2011","unstructured":"Kremer JM, Blanco R, Brzosko M, et al. (2011) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 63:609\u2013621","journal-title":"Arthritis Rheum"},{"key":"3379_CR2","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2008.092866","volume":"68","author":"N Nishimoto","year":"2009","unstructured":"Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J (2009) Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 68:1580\u20131584","journal-title":"Ann Rheum Dis"},{"key":"3379_CR3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/ard.2008.105197","volume":"69","author":"G Jones","year":"2010","unstructured":"Jones G, Sebba A, Gu J, Lowenstein MB, et al. (2010) Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the ambition study. Ann Rheum Dis 69:88\u201396","journal-title":"Ann Rheum Dis"},{"key":"3379_CR4","doi-asserted-by":"crossref","first-page":"858","DOI":"10.3899\/jrheum.130526","volume":"41","author":"R Abdulkader","year":"2014","unstructured":"Abdulkader R, Dharmapalaiah C, Rose G, Shand LM, Clunie GP, Watts RA (2014) Late-onset neutropenia in patients with rheumatoid arthritis after treatment with rituximab. J Rheumatol 41:858\u2013861","journal-title":"J Rheumatol"},{"key":"3379_CR5","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1136\/ard.2007.081166","volume":"67","author":"H Marotte","year":"2008","unstructured":"Marotte H, Paintaud G, Watier H, Miossec P (2008) Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis. Ann Rheum Dis 67:893\u2013894","journal-title":"Ann Rheum Dis"},{"key":"3379_CR6","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1097\/MD.0b013e3181f2caef","volume":"89","author":"O Wolach","year":"2010","unstructured":"Wolach O, Bairey O, Lahav M (2010) Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 89:308\u2013318","journal-title":"Medicine (Baltimore)"},{"key":"3379_CR7","doi-asserted-by":"crossref","unstructured":"Salmon JH, Cacoub P, Combe B, et al (2016) Late-onset neutropenia after treatment with rituximab for rheumatoid arthritis and other autoimmune diseases: data from the autoImmunity and rituximab registry. RMD Open [Internet] http:\/\/www.ncbi.nlm. Nih.gov\/pmc\/articles\/PMC4612695\/","DOI":"10.1136\/rmdopen-2014-000034"},{"key":"3379_CR8","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1038\/sj.leu.2405077","volume":"22","author":"K Stamatopoulos","year":"2008","unstructured":"Stamatopoulos K, Papadaki T, Pontikoglou C, et al. (2008) Lymphocyte subpopulation imbalances, bone marrow hematopoiesis and histopathology in rituximab-treated lymphoma patients with late-onset neutropenia. Leukemia 22:1446\u20131449","journal-title":"Leukemia"},{"key":"3379_CR9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","volume":"106","author":"K Dunleavy","year":"2005","unstructured":"Dunleavy K, Hakim F, Kim HK, et al. (2005) B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis. Blood 106:795\u2013802","journal-title":"Blood"},{"key":"3379_CR10","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/stem.140151","volume":"14","author":"KE Brown","year":"1996","unstructured":"Brown KE, Young NS (1996) Parvoviruses and bone marrow failure. Stem Cells Dayt Ohio 14:151\u2013163","journal-title":"Stem Cells Dayt Ohio"},{"issue":"6","key":"3379_CR11","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1056\/NEJMra030840","volume":"350","author":"NS Young","year":"2004","unstructured":"Young NS, KE B (2004) Parvovirus B19. N Engl J Med 350(6):586\u2013597","journal-title":"N Engl J Med"},{"key":"3379_CR12","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1365-2141.1986.tb05572.x","volume":"63","author":"PW Saunders","year":"1986","unstructured":"Saunders PW, Reid MM, Cohen BJ (1986) Human parvovirus induced cytopenias: a report of five cases. Br J Haematol. 63:407\u2013410","journal-title":"Br J Haematol."},{"key":"3379_CR13","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3899\/jrheum.080930","volume":"36","author":"I Nakamura","year":"2009","unstructured":"Nakamura I, Omata Y, Naito M, Ito K (2009) Blockade of interleukin 6 signaling induces marked neutropenia in patients with rheumatoid arthritis. J Rheumatol 36:459\u2013460","journal-title":"J Rheumatol"},{"key":"3379_CR14","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.ejim.2006.05.002","volume":"17","author":"A Klepfish","year":"2006","unstructured":"Klepfish A, Rachmilevitch E, Schattner A (2006) Parvovirus B19 reactivation presenting as neutropenia after rituximab treatment. Eur J Intern Med 17:505\u2013507","journal-title":"Eur J Intern Med"},{"key":"3379_CR15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.ejim.2004.11.002","volume":"15","author":"V Istomin","year":"2004","unstructured":"Istomin V, Sade E, Grossman Z, Rudich H, Sofer O, Hassin D (2004) Agranulocytosis associated with parvovirus B19 infection in otherwise healthy patients. Eur J Intern Med 15:531\u2013533","journal-title":"Eur J Intern Med"},{"key":"3379_CR16","first-page":"277","volume":"37","author":"N I\u015fik","year":"2003","unstructured":"I\u015fik N, A\u011fa\u00e7fidan A, A\u011firba\u015fli H, et al. (2003) The use of real-time polymerase chain reaction and enzyme immunoassay for the diagnosis of acute parvovirus B19 infections in immunosuppressed patients. Mikrobiyoloji B\u00fcl. 37:277\u2013283","journal-title":"Mikrobiyoloji B\u00fcl."},{"key":"3379_CR17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1111\/j.1365-2141.1993.tb08645.x","volume":"85","author":"K McClain","year":"1993","unstructured":"McClain K, Estrov Z, Chen H, Mahoney DH (1993) Chronic neutropenia of childhood: frequent association with parvovirus infection and correlations with bone marrow culture studies. Br J Haematol. 85:57\u201362","journal-title":"Br J Haematol."},{"key":"3379_CR18","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejim.2006.02.014","volume":"17","author":"K Herzog-Tzarfati","year":"2006","unstructured":"Herzog-Tzarfati K, Shiloah E, Koren-Michowitz M, Minha S, Rapoport MJ (2006) Successful treatment of prolonged agranulocytosis caused by acute parvovirus B19 infection with intravenous immunoglobulins. Eur J Intern Med 17:439\u2013440","journal-title":"Eur J Intern Med"},{"key":"3379_CR19","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1365-2141.1992.tb08894.x","volume":"80","author":"J Pont","year":"1992","unstructured":"Pont J, Puchhammer-St\u00f6ckl E, Chott A, et al. (1992) Recurrent granulocytic aplasia as clinical presentation of a persistent parvovirus B19 infection. Br J Haematol 80:160\u2013165","journal-title":"Br J Haematol"},{"key":"3379_CR20","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0163-4453(00)80018-3","volume":"40","author":"GD Barlow","year":"2000","unstructured":"Barlow GD, McKendrick MW (2000) Parvovirus B19 causing leucopenia and neutropenia in a healthy adult. J Infect 40:192\u2013195","journal-title":"J Infect"},{"issue":"12 Suppl","key":"3379_CR21","first-page":"ECR49","volume":"91","author":"JT Hartmann","year":"2006","unstructured":"Hartmann JT, Meisinger I, Kr\u00f6ber SM, Weisel K, Klingel K, Kanz L (2006) Progressive bicytopenia due to persistent parvovirus B19 infection after immunochemotherapy with fludarabine\/cyclophosphamide and rituximab for relapsed B cell lymphoma. Haematologica 91(12 Suppl):ECR49","journal-title":"Haematologica"},{"key":"3379_CR22","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1007\/s00277-008-0455-2","volume":"87","author":"M Christopeit","year":"2008","unstructured":"Christopeit M, Haak U, Behre G (2008) Late-onset neutropenia following viral bone marrow depression after rituximab therapy. Ann Hematol 87:761\u2013762","journal-title":"Ann Hematol"},{"key":"3379_CR23","doi-asserted-by":"crossref","unstructured":"Barnes TC, Anderson ME, Moots RJ (2011) The many faces of interleukin-6: the role of IL-6 in inflammation, vasculopathy, and fibrosis in systemic sclerosis. Int J Rheumatol 721608","DOI":"10.1155\/2011\/721608"},{"key":"3379_CR24","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/0268-960X(95)90023-3","volume":"9","author":"KE Brown","year":"1995","unstructured":"Brown KE, Young NS (1995) Parvovirus B19 infection and hematopoiesis. Blood Rev 9:176\u2013182","journal-title":"Blood Rev"},{"key":"3379_CR25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1007\/s00277-010-1108-9","volume":"90","author":"J-Y Seo","year":"2011","unstructured":"Seo J-Y, Kim H-J, Kim S-H (2011) Neutropenia in parvovirus B19-associated pure red cell aplasia. Ann Hematol. 90:975\u2013978","journal-title":"Ann Hematol."},{"key":"3379_CR26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2141.1994.tb05136.x","volume":"88","author":"KR Hartman","year":"1994","unstructured":"Hartman KR, Brown KE, Green SW, Young NS (1994) Lack of evidence for parvovirus B19 viraemia in children with chronic neutropenia. Br J Haematol 88:895\u2013896","journal-title":"Br J Haematol"},{"key":"3379_CR27","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood.V91.1.181","volume":"91","author":"J Bux","year":"1998","unstructured":"Bux J, Behrens G, Jaeger G, Welte K (1998) Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 91:181\u2013186","journal-title":"Blood"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3379-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-016-3379-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-016-3379-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T08:03:23Z","timestamp":1601021003000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-016-3379-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,19]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["3379"],"URL":"https:\/\/doi.org\/10.1007\/s10067-016-3379-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,19]]}}}